
# **Traynelis Lab Highlights 2022**

<u>Students</u>: Ullman, Camp; <u>Postdocs</u>: Hao, Perszyk; <u>Visiting Scholar</u>: Lu Zhang; Technicians: Allen, Kim, Sheikh, Zhang; Instructors: Banke, Myers

## **Research topics**

- Develop new subunit-selective NMDA receptor modulators as clinical candidates
- Develop an understanding of variants in the glutamate receptor gene family (GRIN, GRIA)
- Basic research on how glutamate receptors work



# Funding


- R35 grant, Janssen SRA, Simon's Fnd Directors Award
- Dr. Myers and Banke have their own support


#### **Translational**


- Advisory Boards for Sage, Eumentis, GRIN Ther., CureGRIN Fnd, GRIN2B Fnd, CombinedBrain
- Multiple patents filed, licensing discussions for GluN2D-selective NMDA receptor modulators
- NeurOp Inc. completed Phase 1 studies, pursuing funding for Phase 2 studies
- Co-founded of Agrithera with Dennis Liotta
- CFERV is assisting GRIN Therapeutics in patient selection for clinical trial for *GRIN2B* rare variants

## **Productivity**









10 papers over the past 12 months (June 21-June 22), CFERV provided functional data on >600 de novo human mutations